Literature DB >> 14764637

Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.

Annamaria Morelli1, Sandra Filippi, Rosa Mancina, Michaela Luconi, Linda Vignozzi, Mirca Marini, Claudio Orlando, Gabriella Barbara Vannelli, Antonio Aversa, Alessandro Natali, Gianni Forti, Mauro Giorgi, Emmanuele A Jannini, Fabrizio Ledda, Mario Maggi.   

Abstract

By real-time RT-PCR and Western blot analysis, we found that phosphodiesterase type 5 (PDE5) mRNA and protein abundance was several fold higher in human male than in female reproductive tracts. The highest mRNA level (>1 x 10(7) molecules/microg total RNA) was detected in human corpora cavernosa (CC), where PDE5 protein was immunolocalized in both muscular and endothelial compartment. The possible role of androgens in regulating PDE5 expression was studied using a previously established rabbit model of hypogonadotropic hypogonadism. In this model, hypogonadism reduced, and testosterone (T) supplementation restored, CC PDE5 gene and protein expression. In addition, T supplementation completely rescued and even enhanced cyclic GMP conversion to metabolites, without changing IC(50) for sildenafil (IC(50) = 2.16 +/- 0.62 nm). In control CC strips, sildenafil dose-dependently increased relaxation induced by electrical field stimulation, with EC(50) = 3.42 +/- 1.7 nm. Hypogonadism reduced, and T increased, sildenafil effect on electrical field stimulation, again without changing their relative EC(50) values. CC sensitivity to the NO-donor NCX4040 was greater in hypogonadal rabbit strips than in control or T-treated counterparts. Moreover, sildenafil enhanced NCX4040 effect in eugonadal rabbit strips but not in hypogonadal ones. This suggests that androgens up-regulate PDE5 in rabbit penis. We also measured PDE5 gene expression and metabolic activity in human CC from male-to-female transsexual individuals, chronically treated with estrogens and cyproterone acetate. Comparing the observed values vs. eugonadal controls, PDE5 mRNA, protein, and functional activity were significantly reduced. In conclusion, we demonstrated, for the first time, that androgens positively regulate PDE5, thus providing a possible explanation about the highest abundance of this enzyme in male genital tract.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764637     DOI: 10.1210/en.2003-1699

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  65 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 2.  Stuttering priapism: insights into pathogenesis and management.

Authors:  Belinda F Morrison; Arthur L Burnett
Journal:  Curr Urol Rep       Date:  2012-08       Impact factor: 3.092

3.  Nitrergic Mechanisms for Management of Recurrent Priapism.

Authors:  Uzoma A Anele; Arthur L Burnett
Journal:  Sex Med Rev       Date:  2015-06-04

4.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

Review 5.  Normal male sexual function: emphasis on orgasm and ejaculation.

Authors:  Amjad Alwaal; Benjamin N Breyer; Tom F Lue
Journal:  Fertil Steril       Date:  2015-09-16       Impact factor: 7.329

6.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

7.  Effect of phospodiesterase 5 inhibitors on apoptosis and nitric oxide synthases in testis torsion: an experimental study.

Authors:  Hüseyin Ustün; K Turgay Akgül; Ali Ayyildiz; Hatice Yağmurdur; Bariş Nuhoğlu; Ersagun Karagüzel; Elmas Oğüş; Cankon Germiyanoğlu
Journal:  Pediatr Surg Int       Date:  2007-11-06       Impact factor: 1.827

Review 8.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

9.  Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.

Authors:  M Gacci; G Corona; G Apolone; A Apolone; M Lanciotti; N Tosi; S Giancane; L Masieri; S Serni; M Maggi; M Carini
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-03-09       Impact factor: 5.554

10.  The relationship of serum and salivary cortisol levels to male sexual dysfunction as measured by the International Index of Erectile Function.

Authors:  Y Kobori; E Koh; K Sugimoto; K Izumi; K Narimoto; Y Maeda; H Konaka; A Mizokami; T Matsushita; T Iwamoto; M Namiki
Journal:  Int J Impot Res       Date:  2009-05-07       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.